Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

Gautam Borthakur, Hagop Kantarjian, Keyur P. Patel, Farhad Ravandi, Wei Qiao, Stefan Faderl, Tapan Kadia, Raja Luthra, Sherry Pierce, Jorge E. Cortes

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The impact of single versus multiple fms-like tyrosine kinase receptor 3 internal tandem duplication (FLT3-ITD) mutations on the clinical outcome of patients with acute myelogenous leukemia has not been well studied, and particularly has not been investigated while simultaneously accounting for the quantitative mutation burden. METHODS: The authors conducted a multivariate analysis of overall survival, event-free survival, and complete remission duration, including numeric variation (single vs multiple) and quantitative mutant burden of FLT3-ITD as variables among other clinically relevant factors. RESULTS: An analysis of a cohort of 1043 patients with AML demonstrated that, among patients with normal-karyotype acute myelogenous leukemia and FLT3-ITD mutation, overall survival and event-free survival were not affected by the number of FLT3-ITD mutations, but complete remission duration was significantly longer in patients who had multiple FLT3-ITD mutations (median, 86 weeks vs 34 weeks; P =.03). CONCLUSIONS: The current results indicated that time-to-event analyses of patients with normal-karyotype acute myelogenous leukemia and FLT3-ITD mutation should take into account the number of mutations and the mutant burden, among other factors.

Original languageEnglish (US)
Pages (from-to)5819-5822
Number of pages4
JournalCancer
Volume118
Issue number23
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

fms-Like Tyrosine Kinase 3
Receptor Protein-Tyrosine Kinases
Karyotype
Acute Myeloid Leukemia
Mutation
Disease-Free Survival
Survival
Cohort Studies
Multivariate Analysis

Keywords

  • fms-like tyrosine kinase receptor
  • internal tandem duplication mutation
  • internal tandem duplications
  • normal karyotype acute myelogenous leukemia
  • relapse risk

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. / Borthakur, Gautam; Kantarjian, Hagop; Patel, Keyur P.; Ravandi, Farhad; Qiao, Wei; Faderl, Stefan; Kadia, Tapan; Luthra, Raja; Pierce, Sherry; Cortes, Jorge E.

In: Cancer, Vol. 118, No. 23, 01.12.2012, p. 5819-5822.

Research output: Contribution to journalArticle

Borthakur, G, Kantarjian, H, Patel, KP, Ravandi, F, Qiao, W, Faderl, S, Kadia, T, Luthra, R, Pierce, S & Cortes, JE 2012, 'Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia', Cancer, vol. 118, no. 23, pp. 5819-5822. https://doi.org/10.1002/cncr.27571
Borthakur, Gautam ; Kantarjian, Hagop ; Patel, Keyur P. ; Ravandi, Farhad ; Qiao, Wei ; Faderl, Stefan ; Kadia, Tapan ; Luthra, Raja ; Pierce, Sherry ; Cortes, Jorge E. / Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. In: Cancer. 2012 ; Vol. 118, No. 23. pp. 5819-5822.
@article{85161fd983974114bff04db3bd62b46a,
title = "Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia",
abstract = "BACKGROUND: The impact of single versus multiple fms-like tyrosine kinase receptor 3 internal tandem duplication (FLT3-ITD) mutations on the clinical outcome of patients with acute myelogenous leukemia has not been well studied, and particularly has not been investigated while simultaneously accounting for the quantitative mutation burden. METHODS: The authors conducted a multivariate analysis of overall survival, event-free survival, and complete remission duration, including numeric variation (single vs multiple) and quantitative mutant burden of FLT3-ITD as variables among other clinically relevant factors. RESULTS: An analysis of a cohort of 1043 patients with AML demonstrated that, among patients with normal-karyotype acute myelogenous leukemia and FLT3-ITD mutation, overall survival and event-free survival were not affected by the number of FLT3-ITD mutations, but complete remission duration was significantly longer in patients who had multiple FLT3-ITD mutations (median, 86 weeks vs 34 weeks; P =.03). CONCLUSIONS: The current results indicated that time-to-event analyses of patients with normal-karyotype acute myelogenous leukemia and FLT3-ITD mutation should take into account the number of mutations and the mutant burden, among other factors.",
keywords = "fms-like tyrosine kinase receptor, internal tandem duplication mutation, internal tandem duplications, normal karyotype acute myelogenous leukemia, relapse risk",
author = "Gautam Borthakur and Hagop Kantarjian and Patel, {Keyur P.} and Farhad Ravandi and Wei Qiao and Stefan Faderl and Tapan Kadia and Raja Luthra and Sherry Pierce and Cortes, {Jorge E.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/cncr.27571",
language = "English (US)",
volume = "118",
pages = "5819--5822",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

AU - Borthakur, Gautam

AU - Kantarjian, Hagop

AU - Patel, Keyur P.

AU - Ravandi, Farhad

AU - Qiao, Wei

AU - Faderl, Stefan

AU - Kadia, Tapan

AU - Luthra, Raja

AU - Pierce, Sherry

AU - Cortes, Jorge E.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - BACKGROUND: The impact of single versus multiple fms-like tyrosine kinase receptor 3 internal tandem duplication (FLT3-ITD) mutations on the clinical outcome of patients with acute myelogenous leukemia has not been well studied, and particularly has not been investigated while simultaneously accounting for the quantitative mutation burden. METHODS: The authors conducted a multivariate analysis of overall survival, event-free survival, and complete remission duration, including numeric variation (single vs multiple) and quantitative mutant burden of FLT3-ITD as variables among other clinically relevant factors. RESULTS: An analysis of a cohort of 1043 patients with AML demonstrated that, among patients with normal-karyotype acute myelogenous leukemia and FLT3-ITD mutation, overall survival and event-free survival were not affected by the number of FLT3-ITD mutations, but complete remission duration was significantly longer in patients who had multiple FLT3-ITD mutations (median, 86 weeks vs 34 weeks; P =.03). CONCLUSIONS: The current results indicated that time-to-event analyses of patients with normal-karyotype acute myelogenous leukemia and FLT3-ITD mutation should take into account the number of mutations and the mutant burden, among other factors.

AB - BACKGROUND: The impact of single versus multiple fms-like tyrosine kinase receptor 3 internal tandem duplication (FLT3-ITD) mutations on the clinical outcome of patients with acute myelogenous leukemia has not been well studied, and particularly has not been investigated while simultaneously accounting for the quantitative mutation burden. METHODS: The authors conducted a multivariate analysis of overall survival, event-free survival, and complete remission duration, including numeric variation (single vs multiple) and quantitative mutant burden of FLT3-ITD as variables among other clinically relevant factors. RESULTS: An analysis of a cohort of 1043 patients with AML demonstrated that, among patients with normal-karyotype acute myelogenous leukemia and FLT3-ITD mutation, overall survival and event-free survival were not affected by the number of FLT3-ITD mutations, but complete remission duration was significantly longer in patients who had multiple FLT3-ITD mutations (median, 86 weeks vs 34 weeks; P =.03). CONCLUSIONS: The current results indicated that time-to-event analyses of patients with normal-karyotype acute myelogenous leukemia and FLT3-ITD mutation should take into account the number of mutations and the mutant burden, among other factors.

KW - fms-like tyrosine kinase receptor

KW - internal tandem duplication mutation

KW - internal tandem duplications

KW - normal karyotype acute myelogenous leukemia

KW - relapse risk

UR - http://www.scopus.com/inward/record.url?scp=84869500537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869500537&partnerID=8YFLogxK

U2 - 10.1002/cncr.27571

DO - 10.1002/cncr.27571

M3 - Article

C2 - 22605576

AN - SCOPUS:84869500537

VL - 118

SP - 5819

EP - 5822

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -